E-mail: sergio.bracarda@usl8.toscana.it
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- Analysis of European patients enrolled in a global early access protocol with abiraterone acetate for metastatic castration-resistant prostate cancer progressing after chemotherapy
- BEVACIZUMAB (BEV) + LOW-DOSE INTERFERON-α2A (IFN) FOR FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC): FINAL SAFETY AND EFFICACY DATA FROM THE PROSPECTIVE BEVLIN STUDY
- Bevacizumab (BEV) and interferon (IFN) therapy does not increase risk of cardiac events in metastatic renal cell carcinoma (mRCC)
- Bevacizumab/interferon-alpha2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN)
- BEVLiN: Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-α2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC).
- Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-á2a (IFN) in metastatic renal cell carcinoma (mRCC)
- First-line bevacizumab + reduced-dose interferon-alpha2a in patients (pts) with metastatic renal cell carcinoma (mRCC): an update on overall survival
- First-line bevacizumab improves progression-free survival with lower doses of interferon[alpha]2a in the treatment of patients with metastatic renal cell carcinoma (AVOREN)
- What is the impact of subsequent antineoplastic therapy on overall survival (OS) following first-line bevacizumab (BEV)/interferon-alpha2a (IFN) in metastatic renal cell carcinoma (mRCC)? - Experience from AVOREN
